The companies will work together on a new sequencing-based NIPT technology developed by 10x Genomics for the Chinese market.
NGeneBio is moving ahead with plans to have the test cleared for diagnostic use in Korea, while envisioning a 2019 submission to the US FDA.
Executives provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco.
The molecular diagnostic company plans to avoid the IPO process but go public in China through a reverse merger with an auto parts maker.
BioNano plans to develop structural variant assays on its Irys system for diagnostic use in China as a first step in bringing its technology to the clinic.
The assays will incorporate BioNano's Irys next-generation mapping platform, which is designed to image, map, and analyze DNA at the single-molecule level.
Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.
The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.
US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.
In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.